Pramipexole extended release in Parkinson’s disease

References

• Bracco F, Battaglia A, Chouza C et al. The long-acting dopamine receptor agonist cabergoline in early Parkinson’s disease: final results of a 5-year, double-blind, levodopa-controlled study. CNS Drugs18(11), 733–746 (2004).
   PubMed Web of Science ®Google Scholar
• Oertel W, Wolters E, Sampaio C et al. Pergolide versus levodopa monotherapy in early Parkinson’s disease patients: the PELMOPET study. Mov. Disord.21(3), 343–353 (2006).
   PubMed Web of Science ®Google Scholar
• Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinson disease: a randomized controlled trial. Parkinson Study Group. JAMA284(15), 1931–1938 (2000).
   PubMed Web of Science ®Google Scholar
• Holloway R, Shoulson I, Fahn S et al. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch. Neurol.61(7), 1044–1053 (2004).
   PubMed Web of Science ®Google Scholar
• Rascol O, Brooks D, Korczyn A, De Deyn P, Clarke C, Lang A. A five-year study of the incidence of dyskinesia in patients with early Parkinson’s disease who were treated with ropinirole or levodopa. 056 Study Group. N. Engl. J. Med.342(20), 1484–1491 (2000).
   PubMed Web of Science ®Google Scholar
• Fahn S, Elton R. The Unified Parkinson’s Disease Rating Scale. In: Recent Developments in Parkinson’s Disease Volume 2. Fahn S, Marsden CD, Caine BD, Goldstein M (Eds). Macmillan Healthcare Information, NJ, USA, 153–163, 293–304 (1987).
   Google Scholar
• Stowe R, Ives N, Clarke C et al. Dopamine agonist therapy in early Parkinson’s disease. Cochrane Database Syst. Rev.2, CD006564 (2008).
   Google Scholar
• Horstink M, Tolosa E, Bonuccelli U et al. Review of the therapeutic management of Parkinson’s disease. Report of a joint task force of the European Federation of Neurological Societies (EFNS) and the Movement Disorder Society-European Section (MDS-ES). Part II: late (complicated) Parkinson’s disease. Eur. J. Neurol.13(11), 1186–1202 (2006).
   PubMed Web of Science ®Google Scholar
• Miyasaki J, Martin W, Suchowersky O, Weiner W, Lang A. Practice parameter: initiation of treatment for Parkinson’s disease: an evidence-based review: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology58(1), 11–17 (2002).
   PubMed Web of Science ®Google Scholar
• Gerlach M, Double K, Arzberger T, Leblhuber F, Tatschner T, Riederer P. Dopamine receptor agonists in current clinical use: comparative dopamine receptor binding profiles defined in the human striatum. J. Neural Transm.110(10), 1119–1127 (2003).
   PubMed Web of Science ®Google Scholar
• Kohno Y, Takeuchi S. [Pharmacological profiles and clinical effects of antiparkinsonian agent, pramipexole]. Nippon Yakurigaku Zasshi123(6), 429–440 (2004).
   Google Scholar
• Wynalda M, Wienkers L. Assessment of potential interactions between dopamine receptor agonists and various human cytochrome P450 enzymes using a simple in vitro inhibition screen. Drug Metab. Dispos.25(10), 1211–1214 (1997).
   PubMed Web of Science ®Google Scholar
• Jenner P, Könen-Bergmann M, Schepers C, Haertter S. Pharmacokinetics of a once-daily extended-release formulation of pramipexole in healthy male volunteers: three studies. Clin. Ther.31(11), 2698–2711 (2009).
   PubMed Web of Science ®Google Scholar
• Hauser RA, Schapira AH, Rascol O et al. Randomized, double-blind, multicenter evaluation of pramipexole extended release once daily in early Parkinson’s disease. Mov. Disord.25(15), 2542–2549 (2010).
   PubMed Web of Science ®Google Scholar
• Hoehn M, Yahr M. Parkinsonism: onset, progression and mortality. Neurology17(5), 427–442 (1967).
   PubMed Web of Science ®Google Scholar
• Schrag A, Spottke A, Quinn N, Dodel R. Comparative responsiveness of Parkinson’s disease scales to change over time. Mov. Disord.24(6), 813–818 (2009).
   PubMed Web of Science ®Google Scholar
• Guy W. Clinical Global Impressions. ECDEU Assessment Manual for Psychopharmacology. NIH, MD, USA (1976)
   Google Scholar
• Schapira A, Barone P, Hauser R et al. Efficacy and safety of pramipexole extended-release for advanced Parkinson’s disease. In: Proceedings of the 13th Annual International Congress of Parkinson’s Disease and Movement Disorders. Poster WE-199 (2009).
   Google Scholar
• Rascol O, Barone P, Hauser RA et al. Efficacy, safety, and tolerability of overnight switching from immediate- to once daily extended-release pramipexole in early Parkinson’s disease. Mov. Disord.25(14), 2326–2332 (2010).
   PubMed Web of Science ®Google Scholar
• Leopold N, Polansky M, Hurka M. Drug adherence in Parkinson’s disease. Mov. Disord.19(5), 513–517 (2004).
   PubMed Web of Science ®Google Scholar
• Grosset D, Antonini A, Canesi M et al. Adherence to antiparkinson medication in a multicenter European study. Mov. Disord.24(6), 826–832 (2009).
   PubMed Web of Science ®Google Scholar
• Grosset K, Bone I, Grosset D. Suboptimal medication adherence in Parkinson’s disease. Mov. Disord.20(11), 1502–1507 (2005).
   PubMed Web of Science ®Google Scholar
• Claxton A, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin. Ther.23(8), 1296–1310 (2001).
   PubMed Web of Science ®Google Scholar
• Nyholm D, Askmark H, Gomes-Trolin C et al. Optimizing levodopa pharmacokinetics: intestinal infusion versus oral sustained-release tablets. Clin. Neuropharmacol.26(3), 156–163 (2003).
   PubMed Web of Science ®Google Scholar
• Goetz C, Poewe W, Rascol O, Sampaio C. Evidence-based medical review update: pharmacological and surgical treatments of Parkinson’s disease: 2001 to 2004. Mov. Disord.20(5), 523–539 (2005).
   PubMed Web of Science ®Google Scholar
• Valldeoriola F, Cámara A. [Intraduodenal infusion of levodopa]. Rev. Neurol.51(1), 41–48 (2010).
   Google Scholar
• Reichmann H. Transdermal delivery of dopamine receptor agonists. Parkinsonism Relat. Disord.15(Suppl. 4), S93–S96 (2009).
   Google Scholar
• Antonini A, Tolosa E, Mizuno Y, Yamamoto M, Poewe WH. A reassessment of risks and benefits of dopamine agonists in Parkinson’s disease. Lancet Neurol.8(10), 929–937 (2009).
   PubMed Web of Science ®Google Scholar